Current treatment strategies for Parkinsons disease;Therapiestandards in der Behandlung des Morbus Parkinson

Fortschritte der Neurologie Psychiatrie

Volumn 79, Issue 12, 2011, Pages 733-743

  Sudmeyer M ^a   Wojtecki, L ^a   Schnitzler, A ^a  

^a UKD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; PARKINSON DISEASE; AGED; ANIMAL; BRAIN DEPTH STIMULATION; DEMENTIA; DEPRESSION; EUROPE; FEMALE; HUMAN; IMPULSE CONTROL DISORDER; INFUSION PUMP; INTENSIVE CARE; MALE; MIDDLE AGED; MOTOR DYSFUNCTION; PSYCHOSIS; REVIEW; SLEEP DISORDER; TREMOR;

ANTIPARKINSON AGENT; APOMORPHINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

AGED; ANIMALS; ANTI-DYSKINESIA AGENTS; ANTIPARKINSON AGENTS; APOMORPHINE; DEEP BRAIN STIMULATION; DEMENTIA; DEPRESSION; DOPAMINE AGONISTS; EUROPE; FEMALE; HUMANS; IMPULSE CONTROL DISORDERS; INFUSION PUMPS, IMPLANTABLE; INTENSIVE CARE; LEVODOPA; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PARKINSON DISEASE; PSYCHOTIC DISORDERS; SLEEP DISORDERS; TREMOR;

EID: 82955228933     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0031-1281820     Document Type: Article

References (34)

1. Oertel W H., Reichmann H. Parkinson-Syndrome: Diagnostik und Therapie. In: Diener H C. Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart Thieme 2008 82-112
2. Braak H, Del Tredici K. Pathophysiologie des sporadischen Morbus Parkinson. Fortschr Neurol Psychiat 2010 78 (Suppl 1) 2-4
3. Wojtecki L, Südmeyer M, Schnitzler A. Current Treatment of Parkinsons disease. Dtsch Arztebl 2007 104 2513-2522
4. LeWitt P A. Levodopa for the treatment of Parkinsons disease. N Engl J Med 2008 359 2468-2476
5. Koller W C., Hutton J T., Tolosa E et al. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology 1999 53 1012-1019 (Pubitemid 29442117)
6. Stocchi F, Rascol O, Kieburtz K et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease the STRIDE-PD study. Ann Neurol 2010 68 18-27
7. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs. levodopa in early Parkinson disease. Arch Neurol 2009 66 563-570
8. Schade R, Andersohn F, Suissa S et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007 356 29-38 (Pubitemid 46041751)
9. Zanettini R, Antonini A, Gatto G et al. Valvular heart disease and the use of dopamine agonists for Parkinsons disease. N Engl J Med 2007 356 39-46 (Pubitemid 46041752)
10. Onofrj M, Bonanni L, De Angelis M V. et al. Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies. Parkinsonism Relat Disord 2009 15 (Suppl 4) 85-92
11. Fahn S, Shoulson I, Kieburtz K et al. Levodopa and the progression of Parkinsons disease. N Engl J Med 2004 351 2498-2508
12. Schulz J B., Gerlach M, Gille G et al. Basic science in Parkinsons disease: its impact on clinical practice. J Neurol 2011 258 (Suppl 2) 299-306
13. Wallace B A., Ashkan K, Heise C E. et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 2007 130 2129-2145 (Pubitemid 47236623)
14. Rascol O. Disease-modification trials in Parkinson disease: target populations, endpoints and study design. Neurology 2009 72 (Suppl 2) 51-58
15. Olanow C W., Rascol O, Hauser R et al. A double-blind, delayed-start trial of rasagiline in Parkinsons disease. N Engl J Med 2009 361 1268-1278
16. Schapira A H., Albrecht S, Barone P et al. Rationale for delayed-start study of pramipexole in Parkinsons disease: the PROUD study. Mov Disord 2010 25 1627-1632
17. Rascol O, Fitzer-Attas C F., Hauser R et al. A double-blind, delayed-start trial of rasagiline in Parkinsons disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011 10 415-423
18. Kostic V, Przedborski S, Flaster E et al. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinsons disease. Neurology 1991 41 202-205
19. Entacaponeto Tolcapone Switch Study Investigators. Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinsons disease. Mov Disord 2007 22 14-19
20. Rascol O, Brooks D J., Melamed E et al. Rasagiline as an adjunct to levodopa in patients with Parkinsons disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005 365 947-954 (Pubitemid 41071428)
21. Wolf E, Seppi K, Katzenschlager R et al. Long-term antidyskinetic efficacy of amantadine in Parkinsons disease. Mov Disord 2010 25 1357-1363
22. Stocchi F, Giorgi L, Hunter B et al. PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinsons disease. Mov Disord 2011 26 1259-1265
23. Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinsons disease. N Engl J Med 2006 355 896-908 (Pubitemid 44315982)
24. Williams A, Gill S, Varma T et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinsons disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010 9 581-591
25. Follett K A., Weaver F M., Stern M et al. Pallidal versus subthalamic deep-brain stimulation for Parkinsons disease. N Engl J Med 2010 362 2077-2091
26. Fasano A, Romito L M., Daniele A et al. Motor and cognitive outcome in patients with Parkinsons disease 8 years after subthalamic implants. Brain 2010 133 2664-2676
27. Clarke C E., Worth P, Grosset D et al. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinsons disease. Parkinsonism Relat Disord 2009 15 728-741
28. Devos D for the French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinsons disease. Mov Disord 2009 24 993-1000
29. De Gaspari D, Siri C, Cilia A L. et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinsons disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2006 77 450-453
30. Ebersbach G, Ebersbach A, Edler D et al. Comparing exercise in Parkinsons disease the Berlin LSVT BIG study. Mov Disord 2010 25 1902-1908
31. Ramig L O., Sapir S, Countryman S et al. Intensive voice treatment (LSVT) for patients with Parkinsons disease: a 2 year follow up. J Neurol Neurosurg Psychiatry 2001 71 493-498 (Pubitemid 32906873)
32. Menza M, Dobkin R D., Marin H et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009 72 886-892
33. Timmermann L, Maier F, Eggers C et al. Demenz bei Morbus Parkinson: Sinnvolle Diagnostik und rationale Therapie. Fortschr Neurol Psychiat 2010 78 513-518
34. Weintraub D, Koester J, Potenza M N. et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010 67 589-595